- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00965848
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
September 27, 2013 updated by: Janssen-Cilag Ltd.,Thailand
A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after hospital admission), complicated intra-abdominal (in belly) infections and complicated urinary tract infections (bladder infections).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label (all people involved know the identity of the intervention), multi-center (conducted in more than 1 center) study, to evaluate the safety and effectiveness of doripenem in treating Thai participants with nosocomial pneumonia, complicated intra-abdominal and urinary tract infections.
The study consists of 4 visits: Visit 1 (Baseline), Visit 2 (End-of-Treatment [EOT], up to Day 14), Visit 3 (Phone visit, Test-of-Cure [TOC], up to Day 14 after EOT) and Visit 4 (Phone visit, Day 90).
Participants will receive 500 milligram (mg) of doripenem as intravenous infusion (directly into the vein) every 8 hours for at least 3 days after clinical response and extended up to 14 days.
Efficacy will primarily be evaluated by determination of clinical response.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
270
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangkok, Thailand
-
Chiang Mai, Thailand
-
Chiang Rai, Thailand
-
Chonburi, Thailand
-
Khon Kaen, Thailand
-
Khon Khen, Thailand
-
Nakhonratsima, Thailand
-
Nakornnayok, Thailand
-
Pathumthani, Thailand
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Eligibility Criteria:
Inclusion Criteria:
- Male or female participants with 18 years old age and above
- Diagnosed nosocomial pneumonia, complicated intra-abdominal infections and complicated urinary tract infections
- Must have evidence of a systemic inflammatory response syndrome with at least one of the these: fever (body temperature greater than 38 degree celcius) or hypothermia (body temperature less than 36 degree celcius) or elevated total peripheral white blood cell count greater than or equal to 12,000 cells per cubic millimeter or leukopenia with less than 4,000 cells per cubic millimeter or decrease in blood pressure relative to Baseline of greater than 15 millimeter of mercury systolic or increased pulse greater than 100 beats per minute (bpm) and respiratory rates greater than 20 bpm
- Candidate for treatment with carbapenems, with at least one of these conditions: Empirical therapy; suspected infection caused by carbapenem susceptible P. aeruginosa or carbapenem-susceptible A. baumannii or MDR gram negative bacteria or nosocomial infection with failure of previous treatment or modified therapy; known pathogens with resistance to cephalosporins,aminoglycosides, fluoroquinolones or beta-lactam/ batalactamase intibitor and susceptible to carbapenem or known infection caused by gram negative bacteria
- Signed informed consent
Exclusion Criteria:
- Pregnant or lactating female participants
- History of severe allergies to antibiotics such as penicillins, cephalosporins and carbapenems
- Hypersensitivity to doripenem and/or excipients
- Previous use of carbapenems within 7 days of study entry
- Participants in terminal stage of malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nosocomial Pneumonia
Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
|
Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Other Names:
|
EXPERIMENTAL: Complicated Intra-Abdominal Infections
Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
|
Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Other Names:
|
EXPERIMENTAL: Complicated Urinary Tract Infections
Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
|
Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) and Number of Participants Discontinued Because of AEs
Time Frame: Up to 30 days after last dose of study drug
|
An adverse event is any untoward medical occurrence in a participant administered with a pharmaceutical product.
An adverse event does not necessarily have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
The number of participants discontinued because of AEs were also reported.
|
Up to 30 days after last dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Clinical Response at End-of-Treatment (EOT)
Time Frame: Up to Day 14 (EOT)
|
Clinical response was defined as cure, improvement, failure and indeterminate.
Cure=All signs/symptoms resolved/improved/lack of progression of all abnormalities; Improvement=Signs/symptoms of disease improved/resolved/ no modification in antibiotic therapy required & no worsening/appearance of new signs & symptoms of disease; Failure=Persistence or worsening of signs/symptoms of disease or emergence of new signs/symptoms and require any other antimicrobial therapy; and Indeterminate=Insufficient data for treatment evaluation. 2 subjects were lost to follow-up.
|
Up to Day 14 (EOT)
|
Percentage of Participants With Clinical Response at Test-of-Cure (TOC)
Time Frame: Up to Day 14 after End-of-Treatment (EOT)
|
Clinical response was defined as cure, improvement, failure and indeterminate.
Cure=All signs/symptoms resolved/improved/lack of progression of all abnormalities; Improvement=Signs/symptoms of disease improved/resolved/ no modification in antibiotic therapy required and no worsening/appearance of new signs & symptoms of disease; Failure=Persistence or worsening of signs/symptoms of disease or emergence of new signs/symptoms & require any other antimicrobial therapy; & Indeterminate=Insufficient data for treatment evaluation.
The TOC visit (up to Day 14 after EOT) was conducted by phone.
Participants who were assessed as cure or improvement at EOT will be evaluated for clinical response at TOC (up to Day 14 after EOT).
|
Up to Day 14 after End-of-Treatment (EOT)
|
Number of Participants With 90-day Mortality
Time Frame: up to Day 90
|
Number of Participants with 90-day mortality was defined as the number of participants who died by Day 90.
|
up to Day 90
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (ACTUAL)
July 1, 2010
Study Completion (ACTUAL)
July 1, 2010
Study Registration Dates
First Submitted
August 24, 2009
First Submitted That Met QC Criteria
August 25, 2009
First Posted (ESTIMATE)
August 26, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
October 30, 2013
Last Update Submitted That Met QC Criteria
September 27, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Urologic Diseases
- Disease Attributes
- Bacterial Infections and Mycoses
- Iatrogenic Disease
- Infections
- Communicable Diseases
- Healthcare-Associated Pneumonia
- Pneumonia
- Intraabdominal Infections
- Urinary Tract Infections
- Bacterial Infections
- Pneumonia, Ventilator-Associated
- Cross Infection
- Anti-Infective Agents
- Anti-Bacterial Agents
- Doripenem
Other Study ID Numbers
- CR015766
- DORIBAC4003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infections
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineBiomedical Advanced Research and Development AuthorityCompleted
-
GlaxoSmithKlineTerminatedInfections, BacterialAustralia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialAustralia
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
Clinical Trials on Doripenem
-
Johnson & Johnson Pharmaceutical Research & Development...Peninsula Pharmaceuticals, Inc.CompletedBacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
-
Johnson & Johnson Pharmaceutical Research & Development...Peninsula Pharmaceuticals, Inc.Completed
-
PriCara, Unit of Ortho-McNeil, Inc.CompletedPneumonia | Ventilator-Associated Pneumonia | Bacterial Pneumonia | Infections, NosocomialUnited States, Ukraine, Argentina, India, Russian Federation, Croatia, Canada, Chile, France
-
Johnson & Johnson Pharmaceutical Research & Development...Peninsula Pharmaceuticals, Inc.CompletedPneumonia | Ventilators, Mechanical
-
Gary E. Stein, Pharm.D.CompletedFebrile NeutropeniaUnited States
-
Johnson & Johnson Pte LtdJohnson & Johnson (Hong Kong) Ltd.CompletedPneumonia | Urinary Tract Infections | Pneumonia, Ventilator-AssociatedMalaysia, Singapore, Vietnam, Indonesia, Hong Kong
-
Johnson & Johnson Pharmaceutical Research & Development...Peninsula Pharmaceuticals, Inc.CompletedUrinary Tract Infections | Pyelonephritis
-
Medical University of ViennaCompleted
-
Sutep JaruratanasirikulPrince of Songkla UniversityCompletedVentilator-Associated PneumoniaThailand
-
Tan Tock Seng HospitalNational University Hospital, Singapore; Singapore General Hospital; Changi General...WithdrawnBacteremia | Ventilator-associated Pneumonia | Healthcare-associated PneumoniaSingapore